Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas

Neuro-Oncology

Volumn 13, Issue 11, 2011, Pages 1244-1251

  Iwamoto, Fabio M ^a,b   Hottinger, Andreas F ^a,c   Karimi, Sasan ^a   Riedel, Elyn ^a   Dantis, Jocelynn ^a   Jahdi, Maryam ^a   Panageas, Katherine S ^a   Lassman, Andrew B ^a   Abrey, Lauren E ^a   Fleisher, Martin ^a   Deangelis, Lisa M ^a   Holland, Eric C ^a   Hormigo, Adília ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Glioblastoma; Glioma; Serum marker YKL 40

Indexed keywords

GLYCOPROTEIN GP 39;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; GLIOMA; HIGH GRADE GLIOMA; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL PERFORMANCE; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

ADIPOKINES; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BRAIN NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; LECTINS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 80755125534     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor117     Document Type: Article

References (36)

1. Louis DN, International Agency for Research on Cancer, World Health Organization. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: International Agency for Research on Cancer; 2007.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
3. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24(18):2707-2714. (Pubitemid 46630566)
4. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24(18):2715-2722. (Pubitemid 46630567)
5. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. (Pubitemid 40349502)
6. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
7. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol. 2008;5(11):634-644.
8. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol. 2009;27(18):2905-2908.
9. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 2002;62(15):4364-4368. (Pubitemid 34827294)
10. Bhat KP, Pelloski CE, Zhang Y, et al. Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and-2. FEBS Lett. 2008;582(21-22):3193-3200.
11. Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol. 2009;5(7):1065-1082.
12. Shao R, Hamel K, Petersen L, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009;28(50):4456-4468.
13. Johansen JS, Lottenburger T, Nielsen HJ, et al. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2603-2608.
14. Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol. 2004;22(16):3330-3339. (Pubitemid 41103690)
15. Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA, Nordestgaard BG. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol. 2009;27(4):572-578.
16. Schmidt H, Johansen JS, Sjoegren P, et al. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol. 2006;24(5):798-804. (Pubitemid 46622047)
17. Bergmann OJ, Johansen JS, Klausen TW, et al. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin Cancer Res. 2005;11(24 Pt 1):8644-8652. (Pubitemid 43005912)
18. Biggar RJ, Johansen JS, Smedby KE, et al. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res. 2008;14(21):6974-6978.
19. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res. 2003;9(12):4423-4434. (Pubitemid 37248400)
20. Johansen JS, Brasso K, Iversen P, et al. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res. 2007;13(11):3244-3249. (Pubitemid 46944908)
21. Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer. 2004;46(3):333-340. (Pubitemid 39487308)
22. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006;106(5):1130-1139.
23. Hormigo A, Gu B, Karimi S, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res. 2006;12(19):5698-5704. (Pubitemid 44629598)
24. Clarke JL, Iwamoto FM, Sul J, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009;27(23):3861-3867.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216. (Pubitemid 30099779)
26. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280. (Pubitemid 20195640)
27. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med. 1992;11(14-15):1825-1839. (Pubitemid 23015633)
28. Cox D, Oakes D. Analysis of Survival Data. 2nd ed. New York: Chapman & Hill; 1990.
29. Pelloski CE, Mahajan A, Maor M, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res. 2005;11(9):3326-3334. (Pubitemid 40627883)
30. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25(16):2288-2294. (Pubitemid 46954657)
31. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005;65(5):1678-1686. (Pubitemid 40478592)
32. Brennan C, Momota H, Hambardzumyan D, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009;4(11):e7752.
33. Colman H, Zhang L, Sulman EP, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol. 2011;12(1):49-57.
34. Gravendeel LA, Kouwenhoven MC, Gevaert O, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009;69(23):9065-9072.
35. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173. (Pubitemid 43357943)
36. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res. 2005;11(6):2258-2264. (Pubitemid 40490185)